A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/00 (2006.01) A61K 31/245 (2006.01) A61K 31/275 (2006.01) A61K 31/277 (2006.01) A61K 31/341 (2006.01) A61K 31/404 (2006.01) A61K 31/415 (2006.01) A61K 31/423 (2006.01) A61K 31/428 (2006.01) A61K 31/495 (2006.01) A61K 31/50 (2006.01) A61K 31/505 (2006.01) A61K 31/517 (2006.01) A61K 31/519 (2006.01) A61K 35/12 (2006.01) A61K 35/14 (2006.01) A61K 39/385 (2006.01) A61K 39/39 (2006.01) A61K 41/00 (2006.01) A61K 49/00 (2006.01) A61P 37/06 (2006.01) C12Q 1/02 (2006.01) C12N 5/06 (2006.01)
Patent
CA 2450807
A method of inducing immune tolerance in a first mammal to antigens of a second, non-syngeneic, mammal, is disclosed. The method is utilized to minimize graft rejection and/or reduce graft-versus-host diseases in transplantation procedures and to produce hematopoietic mixed chimeras. Methods of determining the activity of tyrphostins and the optimal concentration thereof in this method are also disclosed.
L'invention porte sur un procédé d'induction de tolérance immunitaire chez un mammifère vis-à-vis d'un antigène d'un deuxième mammifère non syngénéïque. Ledit procédé permet de réduire les rejets de greffes et/ou les troubles greffe versus hôte, seconds à des transplantations, et à produire des chimères hématopoïétiques mixtes. L'invention porte également sur une méthode de détermination de l'activité des tyrphostines, et de leur concentration optimale dans le cadre dudit procédé.
Gazit Aviv
Levitzki Alexander
Morecki Shoshana
Slavin Shimon
Hadasit Medical Research Services And Development Ltd.
Ogilvy Renault Llp/s.e.n.c.r.l.,s.r.l.
Yissum Research Development Company Of The Hebrew University Of
LandOfFree
Non-myeloablative tolerogenic treatment with tyrphostins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-myeloablative tolerogenic treatment with tyrphostins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-myeloablative tolerogenic treatment with tyrphostins will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2088749